Статья
КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ УДЛИНЕНИЯ ИНТЕРВАЛОВ QT И QTC НА ФОНЕ ПРИЁМА ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
Увеличение длительности интервала QT является предиктором развития жизнеугрожающего нарушения ритма сердца — желудочковой тахикардии типа «пируэт» (torsade de pointes). Наряду с врождённым, существует и приобретённый синдром удлиненного интервала QT. Известно много лекарственных препаратов, как антиаритмических, так и «некардиальных», которые могут привести к удлинению интервала QT. Список препаратов, вызывающих удлинение интервала QT, постоянно увеличивается и обновляется. В обзоре содержатся современные данные о клиническом значении контроля длительности интервала QT на фоне медикаментозной терапии, приведены примеры состояний, сопровождающихся повышенным риском удлинения интервала QT и, следовательно, развития желудочковой тахикардии типа «пируэт», а также представлен перечень лекарственных препаратов, потенциально могущих привести к увеличению длительности интервала QT.
1. Rautaharju P.M., Surawicz B., Gettes L.S. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part IV: The ST Segment, T and U Waves, and the QT Interval A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Circulation 2009;119:e241–e250
2. Al-Khatib S.M., LaPointe N.M.K., Kramer J.M. What clinicians should know about the QT interval. JAMA2003;289(4): 2120–7.
3. Hannibal G.B. Hasanien A.A., Pickham D. ECG Challenges: Measurement and Rate Correction of the QT Interval. AACN Advanced Critical Care 2013;24(1):90–6.
4. Algra A., Tijssen J.G., Roelandt J.R. et al QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888–94.
5. Straus S.M., Kors J.A., De Bruin M.L. et al Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362–7.
6. Chugh S.S., Reinier K., Singh T. Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery Disease The Oregon Sudden Unexpected Death Study. Circulation 2009;119:663–70.
7. van Noord C., Eijgelsheim M., Stricker B.H.Ch. Drug- and non-drug-associated QT interval prolongation. British Journal of Clinical Pharmacology 2010;70 (1):16–23.
8. Liew R. Electrocardiogram-Based Predictors of Sudden Cardiac Death in Patients With Coronary Artery Disease. Clin. Cardiol. 2011;34(8):466–73.
9. Zhang Y., Post W.S., Blasco-Colmenares E. et al Electrocardiographic QT interval and mortality: a metaanalysis. Epidemiology 2011;22(5):660–70.
10. Zhang Y., Post W.S., Dalal D. et al QT-Interval Duration and Mortality Rate. Results From the Third National Health and Nutrition Examination Survey. Arch Intern Med 2011;171(19):1727–33.
11. Williams E.S.В., Thomas K.L.В., Broderick S.В. et al. Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Data- bank for Cardiovascular Disease (DDCD). Am Heart J 2012;164(3):434–41.
12. Sauer A.J., Newton-Cheh C. Clinical and Genetic Determinants of Torsade de Pointes Risk Circulation 2012;125:1684–94.
13. Yan G.X., Lankipalli R.S., Burke J.F. et al Ventricular repolarization components on the electrocardiogram. Cellular basis and clinical significance. J Am Coll Cardiol 2001;42:401–9.
14. Zareba W., Moss A.J., La Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994;74:550–3.
15. Doschitsin VL. Clinical analysis of electrocardiograms. Moscow: Medicine; 1982. Russian (Дощицин В.Л. Клинический анализ электрокардиограммы. М: Медицина, 1982).
16. Sagie A., Larson M.G., Goldberg R.J. et al An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797–801.
17. Fridericia L.S. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 2003;8:343–51.
18. Meier P., Gloekler1 S., de Marchi S.F. An indicator of sudden cardiac death during brief coronary occlusion: electrocardiogram QT time and the role of collaterals. Eur Heart J 2010; 31:1197–204.
19. Nachimuthu S., Assar M. D., Schussler J.M. Drug-induced QT Interval Prolongation Mechanisms and Clinical Management. Ther Adv Drug Safe 2012;5(3):241–53.
20. Makarov L.M., Chuprova S.N., Kiseleva I.I. Comparison of methods for measuring the QT interval and their clinical significance. Cardiology 2004;(5):71–3. Russian (Макаров Л.М., Чупрова С.Н., Киселева И.И. Сравнение способов измерения интервала Q–T и их клиническое значение. Кардиология 2004;(5):71–73)
21. Chan A., Isbister G., Kirkpatrick C., Dufful S. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007;100:609–15.
22. Higham P.D., Furniss S.S., Campbell R.W.F. Q–T dispersion and components of the Q–T interval in ischemia and infarction. Br Heart J 1995;73:32–6.
23. Moss A.J. Measurement of the Q–T interval and the risk associated with Q–Tc interval prolongation: a review. Am J Cardiol 1993;72:23B–25B.
24. Makarov L.M. Features of the dynamics and the measurement of the QT interval in Holter monitoring. Cardiology 2002;(1):98–102. Russian (Макаров Л.М. Особенности динамики и измерения интервала Q–T при холтеровском мониторировании. Кардиология 2002;(1):98–102)
25. Merri M., Moss A., Benhorin J. et al. Relation between ventricular repolarisation duration and cardiac cycle length during 24-hour Holter recordings: findings in normal patients and patients with long QT syndrome. Circulation 1992;84:1816–21.
26. Panikkath R., Reinier K., Uy-Evanado A. Prolonged Tpeak-to-Tend Interval on the Resting ECG Is Associated With Increased Risk of Sudden Cardiac Death. Circ Arrhythm Electrophysiol 2011;4:441– 7.
27. Kuszakowski M.S. Cardiac arrhythmias. St. Petersburg: IKF Foliant; 1998. Russian (Кушаковский М.С. Аритмии сердца. СПб.: ИКФ Фолиант; 1998).
28. Shkol'nikova M.A., editor. Long QT interval syndrome. Moscow: Medpractika; 2001. Russian (Школьникова М.А., редактор. Синдром удлиненного интервала Q–T. М.:Медпрактика; 2001).
29. Vatutin N.T., Sklyanov E.V., Gritsenko P.V. Long QT syndrome. Cardiology 2002;(9):83–9. Russian (Ватутин Н.Т., Склянная Е.В., Гриценко П.В. Синдром удлиненного интервала QT. Кардиология 2002;(9):83–9).
30. Antzelevitch C. Cellular basis for the repolarization waves of the ECG. Ann N Y Acad Sci 2006;1080:268–81.
31. Butaev T.D., Treshkur T.V., Ovechkin M.A. et al. Congenital and acquired long QT syndrome. St. Petersburg: INKART; 2002. Russian (Бутаев Т.Д,. Трешкур Т.В. Овечкина М.А. и др. Врожденный и приобретенный синдром удлиненного интервала QT. СПб.: ИНКАРТ; 2002).
32. Behr E.R., Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J 2013;34:89–95.
33. Boqueria L.A., Boqueria O.L., Glushko L.A. Mechanisms of cardiac arrhythmias. Annals arrhythmology 2010;(3):69–79. Russian (Бокерия Л. А., Бокерия О. Л., Глушко Л. А. Механизмы нарушений ритма сердца. Анналы аритмологии 2010;(3):69–79).
34. Heist E.K., Ruskin J.N. Drug-Induced Arrhythmia. Circulation 2010;122:1426–35.
35. Goldenberg I., Moss A.J. Long QT Syndrome. J Am Coll Cardiol 2008;51:2291–300.
36. Kulik V.L., Yabluchansky N.I. The QT interval in the cardiac clinic. Bulletin of Kharkov National University. 2009; 879(18):73–96. Russian (Кулик В.Л., Яблучанский Н.И. Интервал QT в кардиологической клинике. Вісн Харк нац ун-ту 2009;879 (18):73–96).
37. Kannankeril P., Roden D. M., Darbar D. Drug-Induced Long QT Syndrome. Pharmacol Rev 2010;62(4):760–81.
38. Doschitsin V.L., Segal E.S., Sedov V.V. ECG QT interval prolongation: classification, clinical significance. Cardiology 1981;(10):22–8. Russian (Дощицин В.Л., Сигал Е.С., Седов В.В. Удлинение интервала Q–T ЭКГ: классификация, клиническое значение. Кардиология 1981;(10):22–8).
39. Yiyi Z., Wendy S.P., Darshan D. et al. Coffee, alcohol, smoking, physical activity and QT interval duration: results from the Third national health and nutritional examination survey. PLoS One 2011;6(2):e17584.
40. Haverkamp W., Breithardt G., Camm A. J. et al The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Research 2000;47:219–33.
41. Yap Y. G., Camm A. J. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363– 72.
42. Kowey P.R., Malik M. The QT interval as it relates to the safety of non-cardiac drugs. Eur Heart J Suppl 2007;9 (Supplement G):G3–G8.
43. Gupta A., Lawrence A. T., Krishnan K. et al Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891–9.
44. Roden D. Drug-Induced Prolongation of the QT Interval. N Engl J Med 2004;350:1013–22.
45. Drew B.J., Ackerman M.J., Funk M. et al Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047–60.
46. Zipes D.P., Camm A.J., Borggrefe M. et al ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Car- diology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247– e346.
47. Straus M., Sturkenboom M.C., Bleumink G.S. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007–12.
48. Roden D. M. Long QT syndrome: reduced repolarization reserve and the genetic link. Journal of Internal Medicine 2006;259:59–69.
49. Jamshidi Y., Nolte I.M., Dalageorgou C. et al Common Variation in the NOS1AP Gene Is Associated With Drug-Induced QT Prolongation and Ventricular Arrhythmia. J Am Coll Cardiol 2012;60:841– 50.
50. Simons G.R., Eisenstein E.L., Shaw L..J, Mark D.B. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardia’s. Am J Cardiol 1997;80:1551–7.
51. Ritter J. M. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol 2012;3(73):331–4.
52. Lopatin Y.M. Diuretics and the development of hyperkalemia in patients with arterial hypertension: Are the security of the original and generic drugs. Atmosphere. Cardiology 2004; (3):12–5. Russian (Лопатин Ю.М. Диуретики и развитие гиперкалиемии у больных артериальной гипертонией: одинакова ли безопасность оригинальных и генерических препаратов. Атмосфера. Кардиология 2004;(3):12–5).
53. National Guidelines for the determining of risk and prevention of sudden cardiac death (draft). Available at: http://www.scardio.ru/downloads/c4m1i1153/ВССрекомендации.pdf. Date of access
54. 06.2013. Russian (Национальные Рекомендации по определению риска и профилактике внезапной сердечной смерти (проект). Доступен на: http://www.scardio.ru/downloads/c4m1i1153/ВСС рекомендации.pdf. Дата доступа: 22.06.2013).
55. Mizusawa Y., Wilde A. A. M. QT Prolongation and Mortality in Hospital Settings: Identifying Patients at High Risk. Mayo Clin Proc 2013;88(4):309–11.
56. Freeman B.D., Dixon D.J., Coopersmith C.M. et al Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008;17(10):971–81.
57. Pickham D., Helfenbein E., Shinn J. A. et al High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study. Critical Care Medicine 2012;2(40):394–9. 316-322.